Curebus Co., Ltd. (CEO Seong-jin Cho), a Seoul Biohub resident company, announced that it has been selected as the "2025 Research Institute Company of the Year" in recognition of its outstanding technology commercialization achievements based on original technologies from public research institutes. The awards ceremony took place on December 18th at the "2025 Research Institute Entrepreneur Night" event held at the Lotte City Hotel in Daejeon.
The "Research Institute Company of the Year" award, jointly hosted by the Korea Research and Development Special Zone Promotion Foundation and the Korea Research Institute Company Association, recognizes research institutes that have demonstrated outstanding achievements in areas such as technological innovation, commercialization, global expansion capabilities, and social value creation. Curebus was recognized as a model research institute company for its achievements across the entire cycle, from technological development to clinical trials and global collaboration.
CureVerse, founded in 2021 based on core technology from the Korea Institute of Science and Technology (KIST), focuses on developing innovative new drugs based on small molecule compounds. Its flagship pipeline, CV-01 (a dementia treatment candidate), has demonstrated its global competitiveness through technology transfer from the preclinical stage to Angelini Pharma in Italy. It is currently undergoing Phase 1 clinical trials in Korea at Seoul National University Hospital.
Additionally, CV-02 (autoimmune disease treatment candidate) received IND approval for phase 1 clinical trials from the US FDA in June, laying the foundation for entering global clinical trials.
Cho Seong-jin, CEO of Curebus, said, “This award is a meaningful example of public research achievements proving their competitiveness in the global market,” and added, “We will continue to expand the success model of research institute companies through technology-based new drug development and contribute to strengthening the nation’s scientific and technological competitiveness.”
- See more related articles
You must be logged in to post a comment.